Quinolone Resistance in Neisseria gonorrhoeae
Janine R. Tompkins1, Jonathan M. Zenilman
1Johns Hopkins University School of Medicine, Ross 1165, 720 Rutland Avenue, Baltimore, MD 21205, USA. jzenilma@jhmi.edu
Abstract:
Single-dose oral quinolones have been recommended for gonorrhea treatment since 1989. The antimicrobial resistance surveillance system has detected several outbreaks of quinolone-resistant gonococcal infections (QRNG), and sporadic treatment failures have been reported from high-incidence areas such as southeast Asia. QRNG may result from mutations that cause structural-functional changes in DNA topoisomerase (the quinolone target enzyme) or by changes in antimicrobial transport into the bacteria. QRNG has occurred sporadically in the United States, predominantly in persons with contact to persons in southeast Asia, and has typically occurred as an epiphenomenon in persons who were treated with other regimens. Nevertheless, this entity warrants close monitoring. The emergence of QRNG is probably related to antimicrobial misuse and overuse, in particular long-term suppressive or subtherapeutic doses.
More Related Videos
07:26Metal-Limited Growth of Neisseria gonorrhoeae for Characterization of Metal-Responsive Genes and Metal Acquisition from Host Ligands
Published on: March 4, 2020
08:58Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Related Concept Videos
Antibiotic Selection
Gene Regulation in Microbial Communities: Quorum Sensing
Development of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial DNA Synthesis
Clinical Significance of Antibiotic Resistance
